Published in Nature on July 22, 2010
Brown and beige fat: development, function and therapeutic potential. Nat Med (2013) 5.29
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature (2011) 4.23
What we talk about when we talk about fat. Cell (2014) 4.12
PPARγ signaling and metabolism: the good, the bad and the future. Nat Med (2013) 3.71
Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science (2013) 3.64
PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab (2012) 3.09
Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell (2012) 3.07
Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell (2012) 2.46
Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances PPARγ activity and insulin sensitivity. Cell (2011) 2.26
Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci (2010) 2.16
TRPV4 is a regulator of adipose oxidative metabolism, inflammation, and energy homeostasis. Cell (2012) 2.03
Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia. Cell Metab (2013) 1.72
Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov (2013) 1.66
Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov (2012) 1.63
PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta (2011) 1.60
DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nat Struct Mol Biol (2011) 1.59
Ligand-dependent perturbation of the conformational ensemble for the GPCR β2 adrenergic receptor revealed by HDX. Structure (2011) 1.54
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab (2014) 1.53
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol (2014) 1.47
Differential hydrogen/deuterium exchange mass spectrometry analysis of protein-ligand interactions. Expert Rev Proteomics (2011) 1.45
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A (2013) 1.45
Minireview: PPARγ as the target of obesogens. J Steroid Biochem Mol Biol (2011) 1.40
Thiazolidinediones regulate adipose lineage dynamics. Cell Metab (2011) 1.30
Multidomain integration in the structure of the HNF-4α nuclear receptor complex. Nature (2013) 1.30
WISP2 regulates preadipocyte commitment and PPARγ activation by BMP4. Proc Natl Acad Sci U S A (2013) 1.30
An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ. Nature (2014) 1.29
Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J Biol Chem (2012) 1.28
Adipogenesis. Cold Spring Harb Perspect Biol (2012) 1.23
Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal (2012) 1.23
Loss of white adipose hyperplastic potential is associated with enhanced susceptibility to insulin resistance. Cell Metab (2014) 1.22
Rosiglitazone, PPARγ, and type 2 diabetes. N Engl J Med (2010) 1.21
Cerebral vascular adaptation to pregnancy and its role in the neurological complications of eclampsia. J Appl Physiol (1985) (2010) 1.21
Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism. Structure (2012) 1.21
Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One (2013) 1.21
Meta-analysis of genome-wide association studies in East Asian-ancestry populations identifies four new loci for body mass index. Hum Mol Genet (2014) 1.20
CDK5 and MEKK1 mediate pro-apoptotic signalling following endoplasmic reticulum stress in an autosomal dominant retinitis pigmentosa model. Nat Cell Biol (2012) 1.17
Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity. Chem Biol (2012) 1.16
Separation of the gluconeogenic and mitochondrial functions of PGC-1{alpha} through S6 kinase. Genes Dev (2011) 1.15
Protein phosphatase 5 mediates lipid metabolism through reciprocal control of glucocorticoid receptor and peroxisome proliferator-activated receptor-γ (PPARγ). J Biol Chem (2011) 1.13
PPARγ regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity. Circ Res (2012) 1.11
CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression. Sci Rep (2013) 1.11
PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress. Mol Endocrinol (2012) 1.10
Amorfrutins are potent antidiabetic dietary natural products. Proc Natl Acad Sci U S A (2012) 1.09
An alternate binding site for PPARγ ligands. Nat Commun (2014) 1.06
PPARs and lipid ligands in inflammation and metabolism. Chem Rev (2011) 1.06
PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty. J Lipid Res (2012) 1.04
PXR antagonists and implication in drug metabolism. Drug Metab Rev (2013) 1.03
Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers. Genes Dev (2014) 1.03
Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. Am J Physiol Endocrinol Metab (2010) 1.03
Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. PLoS One (2011) 1.02
Adiponectin: Probe of the molecular paradigm associating diabetes and obesity. World J Diabetes (2015) 1.01
Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J Biol Chem (2011) 1.01
Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle. Am J Physiol Regul Integr Comp Physiol (2013) 1.00
Innate immune activation in obesity. Mol Aspects Med (2012) 0.99
Targeting the Peroxisome Proliferator-Activated Receptor-γ to Counter the Inflammatory Milieu in Obesity. Diabetes Metab J (2013) 0.99
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J (2012) 0.98
The in vivo role of nuclear receptor corepressors in thyroid hormone action. Biochim Biophys Acta (2012) 0.98
Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists. PLoS One (2012) 0.97
Cognitive enhancement with rosiglitazone links the hippocampal PPARγ and ERK MAPK signaling pathways. J Neurosci (2012) 0.97
Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma. Endocrinology (2011) 0.97
PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation (2011) 0.97
Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci (2012) 0.97
Role of nuclear receptor corepressor RIP140 in metabolic syndrome. Biochim Biophys Acta (2010) 0.96
Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. Cell (2015) 0.96
The multi-level action of fatty acids on adiponectin production by fat cells. PLoS One (2011) 0.96
Green tea polyphenols reduced fat deposits in high fat-fed rats via erk1/2-PPARγ-adiponectin pathway. PLoS One (2013) 0.95
Adipose tissue-resident regulatory T cells: phenotypic specialization, functions and therapeutic potential. Immunology (2014) 0.95
Pharmacological repression of PPARγ promotes osteogenesis. Nat Commun (2015) 0.95
Rationalizing tight ligand binding through cooperative interaction networks. J Chem Inf Model (2011) 0.95
Tissue Tregs. Annu Rev Immunol (2016) 0.94
N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo. J Biol Chem (2011) 0.94
A combined ligand- and structure-based virtual screening protocol identifies submicromolar PPARγ partial agonists. ChemMedChem (2011) 0.94
Transcriptional coregulators: fine-tuning metabolism. Cell Metab (2014) 0.93
Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure. Hypertension (2011) 0.93
Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol (2015) 0.92
Re-thinking cell cycle regulators: the cross-talk with metabolism. Front Oncol (2013) 0.92
A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity. EMBO J (2014) 0.92
Adipocyte SIRT1 knockout promotes PPARγ activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity. Mol Metab (2015) 0.92
Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism. PPAR Res (2015) 0.91
A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity. J Biol Chem (2014) 0.91
Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARγ. Biochim Biophys Acta (2012) 0.91
Activation of AMP-activated protein kinase revealed by hydrogen/deuterium exchange mass spectrometry. Structure (2013) 0.91
PPARγ in vagal neurons regulates high-fat diet induced thermogenesis. Cell Metab (2014) 0.90
GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain. J Biol Chem (2012) 0.90
Regulation of chemokine and chemokine receptor expression by PPARγ in adipocytes and macrophages. PLoS One (2012) 0.90
Cyclin E controls Drosophila female germline stem cell maintenance independently of its role in proliferation by modulating responsiveness to niche signals. Development (2013) 0.90
The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor γ through spatial relocalization at helix 7 of its ligand-binding domain. Mol Cell Biol (2011) 0.89
A structural perspective on nuclear receptors as targets of environmental compounds. Acta Pharmacol Sin (2014) 0.89
Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis. Sci Rep (2015) 0.88
Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis. Open Rheumatol J (2012) 0.88
Obesity: New life for antidiabetic drugs. Nature (2010) 0.88
Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions. PPAR Res (2015) 0.87
The glucocorticoid receptor: cause of or cure for obesity? Am J Physiol Endocrinol Metab (2015) 0.87
Molecular mechanisms regulating vascular tone by peroxisome proliferator activated receptor gamma. Curr Opin Nephrol Hypertens (2015) 0.87
Potential remains for PPAR-targeted drugs. Nat Rev Drug Discov (2010) 0.87
Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem (2012) 0.87
Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery. Mol Pharmacol (2012) 0.87
Appearance and disappearance of the mRNA signature characteristic of Treg cells in visceral adipose tissue: age, diet, and PPARγ effects. Proc Natl Acad Sci U S A (2014) 0.86
Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity. J Comput Aided Mol Des (2011) 0.86
Roles for peroxisome proliferator-activated receptor γ (PPARγ) and PPARγ coactivators 1α and 1β in regulating response of white and brown adipocytes to hypoxia. J Biol Chem (2012) 0.86
Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol (1996) 72.84
Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A (2001) 68.44
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993) 25.54
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 17.58
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med (2001) 16.51
The hormone resistin links obesity to diabetes. Nature (2001) 15.49
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem (1995) 13.34
Adipose tissue as an endocrine organ. J Clin Endocrinol Metab (2004) 11.94
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med (2001) 9.68
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature (1998) 8.33
Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther (1996) 7.12
AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem (1996) 6.93
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A (2001) 6.68
C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev (2002) 6.46
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature (1999) 5.53
Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ (2005) 5.34
A decade of CDK5. Nat Rev Mol Cell Biol (2001) 5.24
A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science (1985) 4.98
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA (2007) 4.25
The adipose organ. Prostaglandins Leukot Essent Fatty Acids (2005) 3.34
Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids. Mol Cell Biol (1996) 3.27
Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem (2001) 3.17
Adipose tissue-derived factors: impact on health and disease. Endocr Rev (2006) 3.16
Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry (2002) 2.97
Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell (1999) 2.71
Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab (2006) 2.70
Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab (2007) 2.69
Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure (2007) 2.57
The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem (1996) 2.47
Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia (2006) 2.07
Severely impaired adipsin expression in genetic and acquired obesity. Science (1987) 2.03
Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol (2003) 1.96
Critical role for Ebf1 and Ebf2 in the adipogenic transcriptional cascade. Mol Cell Biol (2006) 1.86
Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes. Diabetologia (2002) 1.52
Hormonal signaling and transcriptional control of adipocyte differentiation. J Nutr (2000) 1.42
Tumor necrosis factor-alpha regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35. J Biol Chem (2008) 1.30
Sorting nexin 5 is localized to a subdomain of the early endosomes and is recruited to the plasma membrane following EGF stimulation. J Cell Sci (2004) 1.28
Protein conformations, interactions, and H/D exchange. Methods Enzymol (2005) 1.19
Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes (2009) 1.19
Benzoyl 2-methyl indoles as selective PPARgamma modulators. Bioorg Med Chem Lett (2005) 1.17
A functional peroxisome proliferator-activated receptor-gamma ligand-binding domain is not required for adipogenesis. J Biol Chem (2008) 1.16
MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol (2009) 1.10
A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem (2004) 1.00
The giant protein AHNAK involved in morphogenesis and laminin substrate adhesion of myelinating Schwann cells. Glia (2009) 0.97
Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature (2005) 18.41
A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature (2012) 14.67
Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature (2002) 14.37
PRDM16 controls a brown fat/skeletal muscle switch. Nature (2008) 13.08
Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med (2008) 12.41
Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab (2005) 11.66
Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell (2012) 11.03
Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell (2006) 10.18
Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev (2003) 9.93
Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature (2003) 9.77
Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem (2008) 9.56
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 9.53
Adipocytes as regulators of energy balance and glucose homeostasis. Nature (2006) 9.52
Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell (2004) 8.58
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A (2007) 8.23
Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell (2005) 7.07
Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest (2010) 6.96
Transcriptional control of brown fat determination by PRDM16. Cell Metab (2007) 6.79
Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev (2006) 6.68
Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci U S A (2004) 6.53
C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev (2002) 6.46
HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature (2008) 5.85
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev (2012) 5.71
TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science (2005) 5.56
T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol (2008) 5.44
The role of exercise and PGC1alpha in inflammation and chronic disease. Nature (2008) 5.31
PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A (2006) 5.28
STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature (2003) 5.27
Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci U S A (2009) 5.19
Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab (2006) 5.01
Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-beta transcriptional complex. Nature (2009) 4.98
Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci U S A (2006) 4.81
Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab (2005) 4.65
Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1alpha muscle-specific knock-out animals. J Biol Chem (2007) 4.58
A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects. Nature (2011) 4.44
Retracted Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci U S A (2009) 4.37
Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci U S A (2003) 4.34
An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proc Natl Acad Sci U S A (2003) 4.31
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature (2011) 4.23
Peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC-1beta ), a novel PGC-1-related transcription coactivator associated with host cell factor. J Biol Chem (2001) 4.20
Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature (2011) 4.19
Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J Biol Chem (2003) 4.12
Hyperlipidemic effects of dietary saturated fats mediated through PGC-1beta coactivation of SREBP. Cell (2005) 4.04
Regulation of the brown and white fat gene programs through a PRDM16/CtBP transcriptional complex. Genes Dev (2008) 3.90
Effects of Initiating Moderate Alcohol Intake on Cardiometabolic Risk in Adults With Type 2 Diabetes: A 2-Year Randomized, Controlled Trial. Ann Intern Med (2015) 3.78
Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev (2013) 3.74
PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell (2013) 3.71
Molecular mechanisms of cancer development in obesity. Nat Rev Cancer (2011) 3.65
Transcriptional control of preadipocyte determination by Zfp423. Nature (2010) 3.55
Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell (2005) 3.54
Muscle-specific expression of PPARgamma coactivator-1alpha improves exercise performance and increases peak oxygen uptake. J Appl Physiol (1985) (2008) 3.54
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
Insulin-sensitive obesity. Am J Physiol Endocrinol Metab (2010) 3.46
Transcription coactivator TRAP220 is required for PPAR gamma 2-stimulated adipogenesis. Nature (2002) 3.42
A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature (2012) 3.35
Human BAT possesses molecular signatures that resemble beige/brite cells. PLoS One (2012) 3.34
GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab (2006) 3.28
PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab (2012) 3.09
The transcriptional coactivator PGC-1beta drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab (2007) 3.05
Abnormal glucose homeostasis in skeletal muscle-specific PGC-1alpha knockout mice reveals skeletal muscle-pancreatic beta cell crosstalk. J Clin Invest (2007) 3.02
p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. Mol Cell Biol (2004) 3.00
Transcriptional control of brown fat development. Cell Metab (2010) 2.97
Transcriptional control of adipose lipid handling by IRF4. Cell Metab (2011) 2.95
Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. Anal Chem (2006) 2.89
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest (2003) 2.87
Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab (2007) 2.81
Retracted Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab (2008) 2.80
PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev (2007) 2.79
Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci U S A (2006) 2.71
Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab (2007) 2.69
C/EBPβ controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell (2010) 2.68
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature (2012) 2.67
Transcriptional control of brown adipocyte development and physiological function--of mice and men. Genes Dev (2009) 2.66
Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure (2007) 2.57
Molecular mimicry regulates ABA signaling by SnRK2 kinases and PP2C phosphatases. Science (2011) 2.52
Paradoxical effects of increased expression of PGC-1alpha on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism. Proc Natl Acad Sci U S A (2008) 2.49
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48
Zfp423 expression identifies committed preadipocytes and localizes to adipose endothelial and perivascular cells. Cell Metab (2012) 2.41
EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex. Nature (2013) 2.40
Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1alpha: modulation by p38 MAPK. Genes Dev (2004) 2.39
Hypomorphic mutation of PGC-1beta causes mitochondrial dysfunction and liver insulin resistance. Cell Metab (2006) 2.37